Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jun 22, 2010

Probactive and Vietnamese Organization to Combine Antibodies with Radioactive Compounds for Cancer

  • Probactive Biotech and Vietnamese organization Dalat Nuclear Research Institute are collaborating to develop cancer drugs that combine antitumor antibodies and radioactive compounds.

    Probactive Biotech says that it has combined medical-grade iodine-131 and yttrium-90 with antitumor antibodies, producing targeted anticancer activity.

    Parts of the R&D program will be completed at the Dalat Nuclear Research Institute. Clinical trials will be conducted in Vietnam under the regulatory guidelines of the Ministry of Health and also in compliance with FDA regulations.

     



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »